Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Oncomedics reference publications

Oncomedics Reference Publications

CliniSciences presents a selection of reference publications related to the technologies and approaches developed by OncoMedics, including ex vivo chemosensitivity tests, ATP-based assays, organoids, and predictive models for individualized chemotherapy in oncology, particularly in colorectal cancer and peritoneal metastases.

Selected Publications

The Oncogramme® Predicts the Response of Metastatic Ovarian Cancer to Chemotherapeutic Treatment: Link with Patient Care Pathway through Peritoneal Cancer Index, RECIST Criteria 1.1 and Resective Surgical Operability: A Pilot Study

Stéphanie GIRAUD, Tristan GAUTHIER, Ophélie PASINI-CHABOT, Renaud MARTIN, Véronique FERMEAUX, Sandrine LUCE, Pierre-Marie PREUX, Elise DELUCHE, Nicole TUBIANA-MATHIEU, Laurence VENAT, Anne FLOQUET, Frédéric GUYON, Joëlle MOLLARD, Aurélie PERRAUD and Christophe LAUTRETTE

J Cancer Res Therap Oncol. 2026; vol 14: 102.

Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer

Chan Dong Kim, So Hyun Kim, Sang Hoon Jung, Jae Hwang Kim

Ann Surg Treat Res. 2019 Aug;97(2):93-102.

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Kristin Blom, Peter Nygren, Rolf Larsson, Claes R Andersson

SLAS Technol. 2017 Jun;22(3):306-314.

Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC

P Roy, C Canet-Jourdan, M Annereau, O Zajac, M Gelli, S Broutin, L Mercier, A Paci, F Lemare, M Ducreux, D Elias, D Malka, V Boige, D Goéré, F Jaulin

Int J Pharm. 2017 Oct 5;531(1):143-152.

Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer

YONG SIK YOON, CHAN WOOK KIM, SEON AE ROH, DONG HYUNG CHO, TAE WON KIM, MOON BO KIM and JIN CHEON KIM

Anticancer Research. 2017 Mar;37(3):1297-1303.

Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer

Woong Bae Ji, Jun Won Um, Je Seock Ryu, Kwang Dae Hong, Jung Sik Kim, Byung Wook Min, Sung Yeop Joung, Ju Han Lee, Young Sik Kim

Anticancer Res. 2017 May;37(5):2679-2682.

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Kristin Blom, Peter Nygren, Jonathan Alvarsson, Rolf Larsson, Claes R Andersson

J Lab Autom. 2016 Feb;21(1):178-87. [PDF]

In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer

Hye Youn Kwon, Im-Kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee

Cancer Res Treat. 2016 Jul;48(3):970-7.

Precision medicine for cancer with next-generation functional diagnostics

Adam A. Friedman, Anthony Letai, David E. Fisher and Keith T. Flaherty

Nat Rev Cancer. 2015 Dec;15(12):747-56. [PDF]

Role of Conventional Chemosensitivity Test and Tissue Biomarker Expression in Predicting Response to Treatment of Peritoneal Carcinomatosis From Colon Cancer

Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori, Wainer Zoli

Clinical Colorectal Cancer. 2013 Jun;12(2):122-127. [PDF]

Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer

Katsushi Takebayashi, Eiji Mekata, Hiromichi Sonoda, Tomoharu Shimizu, Yoshihiro Endo, Tohru Tani

Cancer Chemother Pharmacol. 2013;72:217-222. [PDF]

Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy

Yong Sik Yoon, Chan Wook Kim, Seon Ae Roh, Dong Hyung Cho, Gyu Pyo Kim, Yong Sang Hong, Tae Won Kim, Moon Bo Kim, Jin Cheon Kim

Anticancer Res. 2012 Aug;32(8):3581-6. [PDF]

Interested in Oncomedics Technologies?

Contact us for more information on ex vivo chemosensitivity tests, predictive assays, or to discuss clinical and preclinical applications.